AbbVie Inc. (ABBV) News

AbbVie Inc. (ABBV): $151.01

-0.71 (-0.47%)

POWR Rating

Component Grades













Filter ABBV News Items

ABBV News Results

Date Symbol Company Title Start End Change POWR Rating
Loading, please wait...

ABBV News Highlights

  • ABBV's 30 day story count now stands at 86.
  • Over the past 29 days, the trend for ABBV's stories per day has been choppy and unclear. It has oscillated between 1 and 8.
  • DRUG, AGE and EYE are the most mentioned tickers in articles about ABBV.

Latest ABBV News From Around the Web

Below are the latest news stories about AbbVie Inc that investors may wish to consider to help them evaluate ABBV as an investment opportunity.

AbbVie's Rinvoq demonstrates efficacy in second late-stage Crohn's study

AbbVie's (ABBV -1.3%) Rinvoq (upadacitinib) met its primary endpoint of clinical remission and endoscopic response at week 12 in a late-stage study in moderate to severe Crohn's disease. Results from the U-EXCEL trial, the second of two phase 3 induction studies, found that a significantly higher number of patients treated with a 12-week...

Seeking Alpha | February 24, 2022

S&P 500 Dividend Aristocrats Fix 4 Buys For March

Foreword As supplement to this article, please note that Kiplinger has published an on-line slide-show detailing the latest 2022 66 S&P Dividend Aristocrats. The article, entitled 66 Best Dividend Stocks You Can Count On in 2022, is by Dan Burrows, a contributing editor. While most of this collection of 66...

Fredrik Arnold on Seeking Alpha | February 24, 2022

Allergan, an AbbVie Company, to Present Data from its Leading Portfolio of Eye Care Treatments at the 2022 American Glaucoma Society (AGS) Annual Meeting

Allergan, an AbbVie (NYSE: ABBV) company, today announced new data to be presented from Allergan's leading portfolio of eye care treatments at the 2022 American Glaucoma Society (AGS) Annual Meeting being held in Nashville, TN and virtually from March 3-6. Presentations will include updated analyses that help further scientific understanding of DURYSTA® (bimatoprost intracameral implant), as well as new data on the XEN® Gel Stent. The DURYSTA data presentations coincide with the two-year anniver

Yahoo | February 24, 2022

Second Phase 3 Induction Study Confirms Upadacitinib (RINVOQ®) Improved Clinical and Endoscopic Outcomes in Patients with Crohn's Disease

AbbVie (NYSE: ABBV) today announced positive top-line results from U-EXCEL, a Phase 3 induction study, showing upadacitinib (45 mg once daily) achieved both primary endpoints of clinical remissiona,b and endoscopic responsec at week 12.1 U-EXCEL is the second of two Phase 3 induction studies to evaluate the safety and efficacy of upadacitinib in adults with moderate to severe Crohn's disease who had an inadequate response or were intolerant to conventional or biologic therapy.1

Yahoo | February 24, 2022

AbbVie Announces Provincial Reimbursement for VENCLEXTA® (venetoclax) with Obinutuzumab for Patients with Previously Untreated Chronic Lymphocytic Leukemia (CLL) in Alberta, Saskatchewan, British Columbia, and Manitoba

AbbVie (NYSE: ABBV) announced today that Alberta, Saskatchewan, British Columbia, and Manitoba now reimburse VENCLEXTA® (venetoclax) in combination with obinutuzumab for the treatment of adult patients with previously untreated chronic lymphocytic leukemia (CLL). The regimen combines six 28-day cycles of obinutuzumab with 12 cycles of VENCLEXTA.1 For full funding criteria, consult the list of medications in effect in each province.2,3,4,5 The combination treatment is also listed on the Drug Bene

Yahoo | February 24, 2022

The Petri Dish: Moderna, Thermo become long-term partners; Karyopharm medical chief departs

The Massachusetts life sciences industry is rife with companies developing drugs and devices to tackle serious diseases, inking new partnership deals, raising money, expanding facilities and more.

Yahoo | February 24, 2022

7 High-Yield Blue-Chip Stocks Suitable for Any Retiree

Income investments are great for volatile times, as investors dump technology stocks and seek steady dividends and capital gains.

Chris Lau on InvestorPlace | February 23, 2022

Healthcare 2022 Outlook: An Attractive Sector In A Difficult Year

Healthcare Pulse The healthcare sector has been in the thick of the pandemic response over the past two years in restoring lives and livelihoods. In 2021, the healthcare sector (NYSEARCA:XLV) lagged the broader market in the first quarter and built up momentum over the final months, closing the year with...

Tarun Chandra, CFA on Seeking Alpha | February 22, 2022

Buffett Dividend Dogs Show 2 To Dig For February

Foreword Dan Burrows and Kyle Woodley say in Kiplinger Investing: "The Berkshire Hathaway portfolio is a diverse set of blue chips and, increasingly, lesser-known growth bets. Here's a look at every stock picked by Warren Buffett and his lieutenants." Any collection of stocks is more clearly understood when subjected to...

Fredrik Arnold on Seeking Alpha | February 22, 2022

7 New ETFs To Consider if You Want To Play Today’s Top Trends

These recently-launched ETFs offer diversification as well as the opportunity to benefit from the emerging industries and trends.

Tezcan Gecgil on InvestorPlace | February 22, 2022

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!

Page generated in 0.4899 seconds.